Get the Stockscreener App
17.94
2.40%
0.42
After Hours:
17.22
-0.72
-4.01%
Novocure Ltd stock is traded at $17.94, with a volume of 588.20K.
It is up +2.40% in the last 24 hours and down -5.93% over the past month.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$17.52
Open:
$17.19
24h Volume:
588.20K
Relative Volume:
0.68
Market Cap:
$1.90B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-12.81
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-2.71%
1M Performance:
-5.93%
6M Performance:
+15.74%
1Y Performance:
+24.67%
1-Day Range:
$17.18
$17.95
1-Week Range:
$17.18
$19.06
52-Week Range:
$11.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
17.94 | 1.90B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
131.93 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Novocure to Report First Quarter 2025 Financial Results - Yahoo Finance
Emerald Advisers LLC Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Proficio Capital Partners LLC Acquires Shares of 30,158 NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Analysts - The AM Reporter
NovoCure Beats Investor Lawsuit Over Cancer Trial Data Results - Bloomberg Law News
Charles Schwab Investment Management Inc. Has $24.92 Million Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Beats Investor Suit Over Cancer Therapy Trial Data (1) - Bloomberg Law News
NovoCure (NASDAQ:NVCR) Rating Increased to Hold at StockNews.com - Defense World
Bank of New York Mellon Corp Increases Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily
Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields - Investing.com India
Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields By Investing.com - Investing.com UK
Principal Financial Group Inc. Invests $272,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure Ltd. to Host Earnings Call - ACCESS Newswire
Truist Financial Corp Invests $340,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World
Don't Ignore The Insider Selling In NovoCure - Simply Wall St
Novocure’s EVP sells shares worth $46,841 By Investing.com - Investing.com Australia
Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus.com
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - MSN
Novocure’s chief innovation officer sells shares worth $5,071 - Investing.com India
Novocure’s EVP sells shares worth $46,841 - Investing.com India
Novocure CEO Ashley Cordova sells shares valued at $38,055 By Investing.com - Investing.com South Africa
Novocure CEO Ashley Cordova sells shares valued at $38,055 - Investing.com
Novocure COO sells shares worth $4,634 By Investing.com - Investing.com Australia
Novocure COO sells shares worth $4,634 - Investing.com
Novocure’s COO Paravasthu Mukund sells shares worth $39,687 By Investing.com - Investing.com Australia
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference - Yahoo Finance
NovoCure (NASDAQ:NVCR) Lowered to “Sell” Rating by StockNews.com - Defense World
NovoCure Executives Cash In: Major Stock Sales Unveiled! - TipRanks
Insider Sell: Uri Weinberg Sells Shares of NovoCure Ltd (NVCR) - GuruFocus.com
NovoCure’s Earnings Call: Growth Amid Challenges - MSN
Novocure executive sells shares for $296,256 By Investing.com - Investing.com South Africa
Novocure’s COO Paravasthu Mukund sells shares worth $39,687 - Investing.com India
Novocure CEO Ashley Cordova disposes shares worth $266,126 - Investing.com India
Novocure CEO Ashley Cordova disposes shares worth $266,126 By Investing.com - Investing.com Canada
Q1 Earnings Estimate for NovoCure Issued By Leerink Partnrs - Defense World
New York State Common Retirement Fund Increases Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World
New York State Common Retirement Fund Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Armenian Reporter
Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25% - Simply Wall St
Los Angeles Capital Management LLC Acquires 55,334 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Rhumbline Advisers Buys 3,115 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure (NASDAQ:NVCR) Posts Earnings Results, Misses Expectations By $0.27 EPS - MarketBeat
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus.com
Commit To Buy NovoCure At $13, Earn 22.3% Using Options - Nasdaq
NovoCure (NASDAQ:NVCR) Shares Gap Down After Earnings Miss - MarketBeat
NovoCure Full Year 2024 Earnings: EPS Misses Expectations - Simply Wall St
NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... - Yahoo Finance
Novocure Reports Strong 2024 Revenue Growth - TipRanks
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025 - Benzinga
Novocure reports Q4 EPS (61c), consensus (34c) - TipRanks
Novocure shares fall as Q4 earnings miss overshadows revenue beat By Investing.com - Investing.com South Africa
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Mar 03 '25 |
Sale |
18.54 |
2,527 |
46,841 |
143,673 |
| Cordova Ashley | Chief Executive Officer |
Mar 03 '25 |
Sale |
18.54 |
2,053 |
38,055 |
204,005 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 03 '25 |
Sale |
18.54 |
250 |
4,634 |
29,173 |
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):